Yoshikazu Hasegawa

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba et al. · JAMA Oncology · 2017 · 978 citations

Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan

Shigeaki Suzuki, Nobuhisa Ishikawa, Fumie Konoeda et al. · Neurology · 2017 · 380 citations

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

Junko Tanizaki, Koji Haratani, Hidetoshi Hayashi et al. · Journal of Thoracic Oncology · 2017 · 223 citations

Biomarker (Medicine), Prognostic Biomarkers, Oncology +9

Krüppel-like factor 5 Is Essential for Blastocyst Development and the Normal Self-Renewal of Mouse ESCs

Masatsugu Ema, Daisuke Mori, Hitoshi Niwa et al. · Cell stem cell · 2008 · 197 citations · Full text

Mouse Escs, Knockout Mouse, Cell Lineage +10

Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

Taroh Satoh, Isamu Okamoto, Masaki Miyazaki et al. · Clinical Cancer Research · 2009 · 175 citations